Somaxon Pharmaceuticals, Inc. (SOMX) Reports Q3 Loss of $0.36,, Sales Fall Short
Tweet
Share
E-mailGet Alerts SOMX Hot Sheet
Price: $3.00 --0%
Financial Fact:
Total operating costs and expenses: 6.62M
Today's EPS Names:
FRMM, PETS, DARE, More
Financial Fact:
Total operating costs and expenses: 6.62M
Today's EPS Names:
FRMM, PETS, DARE, More
Join SI Premium – FREE
Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) reported Q3 EPS of ($0.36), $0.05 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $3.7 million versus the consensus estimate of $4.55 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
- Pan American Silver (PAAS) Misses Q2 EPS by 19c
- Lumexa Imaging Holdings, Inc. (LMRI) Reports In-Line Q2 EPS; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
